Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M
Department of Pathology, Centre Anticancéreux René Huguenin, St.-Cloud, France.
Cancer. 1989 Nov 1;64(9):1914-21. doi: 10.1002/1097-0142(19891101)64:9<1914::aid-cncr2820640926>3.0.co;2-g.
We did a multivariate analysis of 1262 patients with operable, invasive ductal breast carcinoma to assess the prognostic value of the Scarff-Bloom-Richardson (SBR) histologic grading system. Nodal metastasis and SBR were the two most important factors for metastasis-free survival (MFS), P = 10-9 and P = 10-5, respectively, for total study time. In patients who were node negative, the SBR and International Union Against Cancer (UICC) stages were the most important for MFS (P = 4 X 10-4 and P = 0.03). In order to try to improve the SBR prognostic value, we first studied the three components of the SBR separately: ductoglandular differentiation proved the least predictive and nuclear pleomorphism and mitotic index the most predictive. A rearrangement of the two nuclear scores alone produced higher risk values and better risk separation of patient subpopulations than SBR, and eliminated the SBR from the multivariate model. This rearrangement, modified SBR (MSBR), defined five new risk subgroups with statistically different risk ratios for MFS (P = 3 X 10-8). SBR grade II (55% of patients) was separated into three MSBR groups significantly different according to MFS (P = 0.008). In the patients who were node negative, MSBR replaced the SBR and was the most important factor for prediction of relapse of MFS (P less than 0.00001). The MSBR is more accurate and predictive than the standard SBR grade and is particularly useful when the nodal status of the patient is negative or unknown.
我们对1262例可手术的浸润性导管癌患者进行了多因素分析,以评估斯卡夫-布卢姆-理查森(SBR)组织学分级系统的预后价值。淋巴结转移和SBR是无转移生存期(MFS)的两个最重要因素,在整个研究期间,其P值分别为10^-9和10^-5。在淋巴结阴性的患者中,SBR和国际抗癌联盟(UICC)分期对MFS最为重要(P = 4×10^-4和P = 0.03)。为了提高SBR的预后价值,我们首先分别研究了SBR的三个组成部分:导管腺分化的预测性最差,核多形性和有丝分裂指数的预测性最强。仅对两个核评分进行重新排列产生的风险值更高,患者亚组的风险分离效果更好,且在多因素模型中取代了SBR。这种重新排列的改良SBR(MSBR)定义了五个新的风险亚组,其MFS的风险比在统计学上有显著差异(P = 3×10^-8)。SBR II级(占患者的55%)根据MFS被分为三个差异显著的MSBR组(P = 0.008)。在淋巴结阴性的患者中,MSBR取代了SBR,是预测MFS复发的最重要因素(P小于0.00001)。MSBR比标准SBR分级更准确、更具预测性,在患者淋巴结状态为阴性或未知时尤其有用。